Drug Profile
Research programme: demyelinating disorder therapeutics - Rewind Therapeutics
Latest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator Rewind Therapeutics
- Class Neuroprotectants; Small molecules
- Mechanism of Action G protein-coupled receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple sclerosis; Neurological disorders
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for research development in Neurological-disorders in Belgium
- 28 Feb 2022 No recent reports of development identified for research development in Multiple-sclerosis in Belgium
- 02 Sep 2020 Rewind Therapeutics plans clinical trials for demyelinating disorder therapeutics for Neurological disorders (myelin related diseases)